How will protein biomarkers influence the future of global healthcare?

Clinical care for the most part still adheres to a one-size-fits-all approach, based on strategies that have been developed for the “average” person, with less consideration of individual differences. The move to more stratified medicine that delivers the right treatment to the right patient at the right time represents the next great movement for global healthcare, but also a colossal challenge for science. Protein biomarker strategies will be key to these developments, helping to us to better understand the biology of disease, to develop new, better and more targeted drugs, and to provide them to the right patients in a more stratified and effective manner.

"Protein Biomarker Symposium 2019" is an invitation-only symposium that will bring together some of the leading researchers in this field, to present their work to an invited audience of like-minded colleagues, and to stimulate a creative discussion on recent progress and future challenges. To REGISTER for the symposium, please use the link provided in your invitation email.

In connection with the main event, there will also be three closed-session satellite meetings on June 5: One focused on protein biomarkers for inflammatory bowel disease (IBD), an interactive, experience-sharing symposium for core laboratories who run the Olink platform, and a workshop around the SCALLOP consortium for discovery and follow-up of genetic associations with protein biomarkers identified using the Olink platform. Welcome to Boston!
Professor Robert Gerszten

Speaker roster

Genevieve Boland, MD, PhD

Genevieve M. Boland, MD, PhD, FACS is Director of the Melanoma Surgery Program and Director of the MGH Surgical Oncology Research Laboratories at the Massachusetts General Hospital.  She is board certified in General Surgery and Complex General Surgical Oncology, and she is a Fellow of the American College of Surgeons. Dr. Boland leads the MGH melanoma translational and correlative research efforts in immuno-oncology. She is the PI of the Melanoma and GI Tumor Repositories and her research utilizes patient-derived specimens to identify and characterize pathways and cell types responsible for response and resistance to targeted therapy and immunotherapy in various solid tumor types. She works as part of the Severe Immunotherapy Complication (SIC) service at MGH to define the clinical markers of immune checkpoint-related toxicities and identify biomarkers for immune related adverse events.

Robert Gerszten, MD, PhD

Robert E. Gerszten, MD is Chief of Cardiology at Beth Israel Deaconess Medical Center, the Herman Dana Professor of Medicine at Harvard Medical School, and a Senior Associate Member of the Broad Institute. Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases.

His translational research program leverages metabolomic and proteomic technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His work is funded by the NIH and the American Heart Association, from whom he received an Established Investigator Award. Dr. Gerszten is a member of the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists. He is a recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School.

Arthur Gilly, PhD

Dr. Arthur Gilly has a background in engineering, applied mathematics and computer science and holds a PhD in computational genetics from the University of Cambridge. He worked at the Sanger Institute in Ele Zeggini's lab as a Principal Bioinformatician for 5 years, and is now Head of Analytics at the Institute of Translational Genomics at the Helmholtz Centre in Munich. His main interest has been on innovative methodologies for studying the genetics of complex traits, with a focus on population isolates.

Steven Grinspoon, MD

Dr. Grinspoon is a Professor of Medicine, Harvard Medical School, Director of the MGH Program in Nutritional Metabolism, Director of the Nutrition Obesity Research Center at Harvard and Endowed Chair in Neuroendocrinology and Metabolism. He has had a long-standing interest in the mechanisms and treatment strategies for cardiovascular disease in HIV Disease. His contributions include the first demonstration of increased arterial inflammation in association with immune activation in HIV, and demonstration of atypical vulnerable coronary plaque lesions in this population.  He Chaired the American Heart Association State of the Science Conference on Cardiovascular Disease in HIV-infected patients. e is Co-PI, of the REPRIEVE trial, the largest CVD primary prevention trial in HIV, enrolling over 7500 patients in 11 different countries. For his work Dr. Grinspoon was awarded the 2016 Aurbach Laureate award in translational research from the Endocrine Society.

Emma Guttman, MD, PhD

Emma Guttman-Yassky, MD, PhD, Sol and Clara Kest Professor of Dermatology and Immunology, Vice Chair of the Department of Dermatology, Director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. She earned her M.D. from Sackler in Tel-Aviv, and a Ph.D. from Bar-Ilan, Israel. After her Israeli Board certification in dermatology, Dr. Guttman moved to the U.S. to pursue a postdoctoral fellowship at The Rockefeller University and a second dermatology residency at Weill-Cornell, NY. Dr. Guttman’s major focus is atopic dermatitis/AD. She made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology, opening the door to new therapeutics.She was elected to the American Society for Clinical Investigation/ASCI, the American Dermatological Society/ADA, and received the Young Investigator Award (2011) from the AAD.

Jonas Halfvarson, MD, PhD

Jonas Halfvarson is Senior Physician and Associate Professor at Örebro University Hospital, Sweden. He combines his time in clinical practice with his positions at Örebro University. Dr Halfvarson obtained his PhD for research on IBD in twins, and heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of Inflammatory Bowel Diseases (SOIBD) and serves as the Scientific Director of the Swedish national quality registry for IBD (SWIBREG). His research focuses on biomarkers in IBD, from both a clinical and mechanistic perspective.

Dr Halfvarson was named a Rising Star in Gastroenterology at the United European Gastroenterology Week (UEGW) in 2011 and is a board member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). He has contributed to numerous impactful clinical studies across multiple facets of IBD, and has over 120 peer-reviewed publications

Jamie Heywood

An MIT-trained mechanical engineer, Jamie entered the field of translational medicine when his 29 year-old brother, Stephen, was diagnosed with ALS/Lou Gehrig’s Disease. Described by CNN Money as one of the 15 companies that will change the world, Jamie co-founded PatientsLikeMe to ensure patient outcomes become the primary driver of the medical care and discovery process. Jamie is also the founder and past CEO of the ALS Therapy Development Institute (ALS TDI), the world’s first non-profit biotechnology company. During his tenure at ALS TDI, Jamie helped pioneer an open research model and industrialized therapeutic validation process that made ALS TDI the world’s largest and most comprehensive ALS research program. Jamie has founded or co-founded three other healthcare companies: AOBiome, Genetic Networks, and TheSocialMedwork, and is an active member of a community of innovators working to bring dramatic improvements to the way we discover, develop and deliver effective health. .

Michael Howell, PhD

Michael Howell currently works as the Senior Director of Translational Research at the Incyte Corporation with a focus on immunological and inflammatory diseases.  Dr. Howell received his PhD in Immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health.  While at National Jewish, Michael transitioned to the faculty and served as a Co-Investigator for the Atopic Dermatitis Vaccinia Network.  Since transitioning to industry, Dr. Howell has held positions at Boehringer Ingelheim, the Immune Tolerance Network, and MedImmune/AstraZeneca.  Throughout his career, Dr. Howell has combined clinical, translational, and basic science approaches to identify personalized medicine approaches to treat inflammatory and immunological diseases.  This has been highlighted in national and international meetings, publications, and patents for therapeutic interventions and biomarker strategies.

Anders Mälarstig, PhD

Anders Malarstig, PhD, is Director of Target Sciences at Pfizer Worldwide Research and Development, as well as an affiliate researcher at the Karolinska Institute. Dr. Malarstig obtained his PhD under professors Agneta Siegbahn and Lars Wallentin at Uppsala University, before taking up a postdoctoral research position in cardiovascular genetics and vascular biology at the Karolinska Institute. He then joined Pfizer in the UK as group leader of the Human Genetics unit, focusing on respiratory disease and chronic pain. In his current position with Pfizer in Stockholm, Dr. Mälarstig is responsible for developing and applying strategies for new drug targets and precision medicine

Svati Shah, MD

Dr. Svati H. Shah is a physician scientist, Professor of Medicine, Vice-Chief of Translational Research and Director of the Adult Cardiovascular Genetics Clinic in the Division of Cardiology, Department of Medicine; a faculty member and Co-Director of Translational Research in the Duke Molecular Physiology Institute (DMPI); and a faculty member in the Duke Clinical Research Institute (DCRI). Her research focus is on metabolic and genetic pathways of cardiometabolic diseases, integrating diverse genomic, metabolomic and proteomic techniques for identification of novel mechanisms of disease and biomarkers. Her multi-disciplinary molecular epidemiology lab within the DMPI has quantitative and molecular components and leverages large human cohorts for discovery studies using omics technologies with subsequent functional validation for mechanistic insight. Dr. Shah also collaborates closely with the DCRI for biomarker discovery in clinical trials and she is the Duke PI for the Verily Project Baseline study.

Charlotte Teunissen, PhD

Charlotte Teunissen’s mission is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group cover the entire spectrum of biomarker development, starting with biomarker identification, followed by biomarker assay development and analytical validation, and extensive clinical validation to ultimately implement novel biomarkers in clinical practice.

Charlotte’s idea is that collaboration is a prerequisite for performing high quality biomarker studies, and she has thus taken a lead in several collaborative networks, such as the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization consortium.

Lars Wallentin, MD, PhD

Lars Wallentin is senior professor of Cardiology and founder and first leader of the Uppsala Clinical Research Centre (UCR) at Uppsala University Hospital, Uppsala, Sweden. In 1991, he became the first Professor of Cardiology at Uppsala University, where he founded and was head of the Department of Cardiology from 1991 to 1999. In 2001, Lars Wallentin founded the Uppsala Clinical Research Center (UCR), which is a centre for major international clinical trials and their biobanks for biochemical and genetic analysis.

Lars Wallentin’s research has been devoted since the mid-1980s to acute coronary syndrome and he has published more than 700 papers in peer-reviewed international journals and has received the Gold Medal of ESC and several other prestigious awards. Among his distinctions, he has been awarded the European Society of Cardiology’s Gold Medal for outstanding contributions to cardiac research. In 2012, Lars Wallentin was made an honorary citizen of Uppsala in recognition of his services to society

Johan Lund MD, PhD

Dr Johan Lund is currently CEO of KyNexis, a startup company he has co-founded in Sweden. Prior to this he spent 20 years in pharmaceutical industry leading Research and Early Development groups within Celgene, Pfizer and AstraZeneca in Sweden, UK and USA. Earlier in his career Dr Lund was Professor and Chairman of the Anatomy and Cell Biology Department, University of Bergen Medical Faculty. He received his medical training at the Karolinska Institutet in Stockholm where he also obtained his Ph.D, followed by post-doctoral training at UT Southwestern in Dallas. Dr Lund will moderate the symposium


Take a look at our short video summary of last year’s symposium in Stockholm

Practical information

Venue – Joseph B. Martin Conference Center at Harvard Medical School, Boston.

The Joseph B. Martin Conference Center venue is located within the New Research Building at Harvard Medical School, It is placed in the heart of Boston’s Longwood Medical Area, and is an ideal location for all attendees to get to know what the Harvard “experience” is all about. See more information here

77 Avenue Louis Pasteur
MA 02115

Experience Boston

If you are coming to the symposium from out of town and have the opportunity, this is a great team to explore the historic and vibrant city of Boston!
Online information
Can we help you with something?
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
About the conference
"Protein Biomarker Symposium 2019" is an international one-day symposium, hosted by Professor Robert Gerzsten and sponsored by Olink Proteomics. The meeting will focus on how protein biomarker-based strategies can influence and drive the development of a more stratified approach to healthcare, and help to realize the potential of "precision medicine". As well as featuring presentations from some of the world's leading researchers in this field, the event aims to provide a forum where academia and industry can exchange views and forge collaborations, interactions that are essential for the future of global healthcare. Attendance is strictly by invitation only, but if you have any questions or comments about this or future events, please use the simple form above.